Lanreotide In Polycystic Kidney Disease Study

Summary

LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double blind placebo controlled study. The main objective is to prove that lanreotide, a somatostatin analog, is able to reduce the glomerular filtration rate decline over 3 years by at least 30%. Cardiovascular outcomes, blood pressure, quality of life and safety are among the secondary outcomes. The study, which will include 180 ADPKD patients, is scheduled to start in early 2014. An equal number of patients with chronic kidney disease stage 2 (90 patients with GFR 89 to 60 ml/mn/1.73 m2) and chronic kidney disease stage 3 (90 patients with GFR 59 to 30 ml/mn/1.73 m2) will be included. The primary endpoint (GFR decline) will be assessed by repeated measures, in the overall population as well as in the two GFR stratus.

Timeline

Start

2014-09-19

Primary completion

2019-07-31

Completion

2019-07-31

Publications

• Joly D, Ursino M, Bienaime F, El Karoui K, Karras A, Thervet E, Boffa JJ, Galichon P, Luque Y, Michel PA, Cartery C, Vrtovsnik F, Daugas E, Peraldi MN, Colas S, Semeraro M, Treluyer JM, Meyzer C, Hummel A, Fouchard M, Nguyen-Khoa T, Knebelmann B, Alberti C. A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease. Kidney Int. 2026 Jun 19:S0085-2538(26)00498-9. doi: 10.1016/j.kint.2026.05.018. Online ahead of print.
• St Pierre K, Cashmore BA, Bolignano D, Zoccali C, Ruospo M, Craig JC, Strippoli GF, Mallett AJ, Green SC, Tunnicliffe DJ. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.

Drugs

Indications